'Less Is More' When it Comes to Testicular Cancer Chemo, Study Suggests

Title: 'Less Is More' When it Comes to Testicular Cancer Chemo, Study SuggestsCategory: Health NewsCreated: 1/9/2020 12:00:00 AMLast Editorial Review: 1/10/2020 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news

Related Links:

Cure rates for stage 1 testicular cancer are reaching 100%. However, long ‐term treatment‐related side effects pose their own health risks. Regular follow up and monitoring are important for early detection and timely treatment of conditions such as testosterone deficiency and metabolic syndrome.
Source: Trends in Urology and Men's Health - Category: Urology & Nephrology Authors: Tags: Oncology Source Type: research
Conclusion: MRI with DWI is as good as CT in detection of retroperitoneal lymph node metastases regardless of lymph node size, and it can be used as part of follow-up of testicular cancer patients instead of ionizing radiation producing imaging methods. PMID: 32048533 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusion: Collated to the Comparison Group, the kidney function in TCSs became increasingly impaired during nearly three post-treatment decades, related to the treatment modality. Early detection and intervention of kidney dysfunction is important to reduce the risk of TCSs' long-term morbidity and mortality related to nephrotoxicity, such as cardio-vascular diseases. PMID: 32043400 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Abstract The aims of this study were to determine the prognostic value of primary tumor surgery and identify optimal candidates for such surgery among patients with seminoma and distant metastasis at diagnosis. We identified 521 patients with seminoma and distant metastasis at diagnosis between 2004 and 2014 from the Surveillance, Epidemiology, and End Results database. Among these patients, 434 had undergone surgery, whereas 87 had not. The prognostic value of primary tumor surgery was assessed by Kaplan-Meier methods, log-rank analyses, and multivariate Cox's proportional hazards model. Survival curves and fores...
Source: Asian Journal of Andrology - Category: Urology & Nephrology Authors: Tags: Asian J Androl Source Type: research
No abstract available
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: TESTICULAR CANCER: Edited by Axel Heidenreich and Siamak Daneshmand Source Type: research
Purpose of review The presence of vascular solid tumors within the testicle is considered to be malignant until proven otherwise. However, it is prudent for clinicians to be aware of rare benign and malignant intratesticular lesions as management can differ from the established treatment algorithms for germ-cell tumors. Recent findings Utilizing certain histopathologic findings can assist with the diagnosis of rare testis tumors. Often times the tumor subtypes are an important consideration in the grading and classification of the disease, which drives management. The multidisciplinary management of rare malignant tes...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: TESTICULAR CANCER: Edited by Axel Heidenreich and Siamak Daneshmand Source Type: research
Purpose of review Approximately 30% of clinical stage 1 (CS1) nonseminomatous germ cell tumours (NSGCT) and 15–20% of CS1 seminoma relapse without adjuvant treatment. Despite this, the 5-year survival for CS1 is 99%. The purpose of this review is to assess if active surveillance should be standard for all patients with CS1 testis cancer independent of risk factors. Recent findings Recent data from Princess Margaret Cancer Centre suggest a nonrisk-adapted surveillance approach avoids treatment in ∼70% of patients. Most relapse early at a median time of 7.4 months. The majority of relapses are confined to the ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: TESTICULAR CANCER: Edited by Axel Heidenreich and Siamak Daneshmand Source Type: research
Purpose of review Early-stage testicular cancers are highly curable. Following orchidectomy, management options for stage I disease include active surveillance, nerve-sparing retroperitoneal lymph node dissection (nsRPLND) and primary chemotherapy as recommended by the current guidelines. Primary RPLND has for decades played an integral part of treatment in patients with early-stage testicular germ cell tumors (TGCT), particularly in nonseminomatous germ cell tumors (NSGCT) with focus on reducing the long-term morbidity. We review the role of RPLND in stage I NSCGT as well as stage II A/B NSGCT and as seminoma. Recent f...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PENIS CANCER: Edited by Oscar R. Brouwer and Daher C. Chade Source Type: research
More News: Cancer | Cancer & Oncology | Study | Testicular Cancer